脳腫瘍治療薬市場：タイプ別、治療法別、患者年齢層別、流通チャネル別、エンドユーザー別-2025-2030年の世界予測

脳腫瘍治療薬市場は、2023年に30億3,000万米ドルと評価され、2024年には32億8,000万米ドルに達すると予測され、CAGR 8.24％で成長し、2030年には52億8,000万米ドルに達すると予測されています。

脳腫瘍治療薬市場の範囲と定義には、脳腫瘍の管理と治癒の可能性を目的とした医薬品、外科的介入、放射線療法を含む一連の治療が含まれます。これらの治療の必要性は、脳腫瘍の世界の有病率の増加から生じており、専門的な治療を必要とするこれらの病態の複雑な性質によって強調されています。脳腫瘍治療薬の最終用途は、主に病院、専門のがん治療センター、研究機関であり、そこでは患者の即時治療と、より効果的な治療法の長期的研究の両方に重点が置かれています。市場に影響を与える主な成長要因としては、標的療法や免疫療法などの医薬品開発における技術的発展、製薬企業による研究開発投資の増加、早期診断や治療オプションに対する意識の高まりなどが挙げられます。潜在的なビジネスチャンスは、個別化医療アプローチの採用拡大や、診断・治療の精度向上のための人工知能の統合にあります。しかし、高い治療費、規制上のハードル、臨床試験の複雑さなどの課題は、市場成長に大きな制約を課します。さらに、脳腫瘍の不均一性と血液脳関門は、有効な治療法を開発する上で特有の科学的課題を突きつけています。これらを克服するためには、遺伝子治療、ナノ粒子ベースのドラッグデリバリーシステム、精密医療のためのバイオマーカーの使用など、新規治療法の探求が革新と研究の最良の分野となります。これらの技術革新は、治療効果を高めるだけでなく、従来の治療に伴う副作用を軽減する可能性もあります。市場の競争は激しく、製品ポートフォリオの拡大を目指した継続的な進歩や買収がその原動力となっています。成長を実現するために、利害関係者は研究開発のための戦略的パートナーシップに注力し、臨床試験の合理化を図り、様々なタイプの脳腫瘍の治療におけるアンメットニーズに対応する、拡張可能で費用対効果の高い治療法に投資すべきです。

市場力学：急速に進化する脳腫瘍治療薬市場の主要市場インサイトを公開

脳腫瘍治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 脳腫瘍およびその他の神経疾患の罹患率の上昇
  • 腫瘍の存在を検出する検査に対するニーズの高まり
  • 分子診断学における研究活動
• 市場抑制要因
  • 診断と治療に伴う高コスト
• 市場機会
  • ヘルスケア支出の増加と有利な償還政策
  • がん啓発のための政府の取り組み
• 市場の課題
  • 脳腫瘍治療薬に関連する副作用

ポーターの5つの力：脳腫瘍治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、脳腫瘍治療薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：脳腫瘍治療薬市場における外部からの影響の把握

外部マクロ環境要因は、脳腫瘍治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析脳腫瘍治療薬市場における競合情勢の把握

脳腫瘍治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス脳腫瘍治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、脳腫瘍治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨脳腫瘍治療薬市場における成功への道筋を描く

脳腫瘍治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 脳腫瘍やその他の神経疾患の発生率の上昇
    • 腫瘍の存在を検出する検査の必要性が高まる
    • 分子診断に関する調査活動
  • 抑制要因
    • 診断と治療にかかる高額な費用
  • 機会
    • ヘルスケア費の増大と有利な償還政策
    • がん啓発のための政府の取り組み
  • 課題
    • 脳腫瘍治療薬に関連する副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 脳腫瘍治療薬市場：タイプ別

• 神経膠芽腫
• 髄膜腫
• 転移性脳腫瘍
• 下垂体腫瘍

第7章 脳腫瘍治療薬市場セラピー

• 化学療法
• 遺伝子治療
• 免疫療法
• 放射線治療
• 標的療法
• 組織工学

第8章 脳腫瘍治療薬市場患者の年齢層別

• 成人用
• 小児科

第9章 脳腫瘍治療薬市場：流通チャネル別

• オフライン薬局
• オンライン薬局

第10章 脳腫瘍治療薬市場：エンドユーザー別

• 外来手術センター
• 病院
• 専門クリニック

第11章 南北アメリカの脳腫瘍治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の脳腫瘍治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの脳腫瘍治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Adcendo ApS
• AIVITA Biomedical, Inc.
• Amgen Inc.
• AstraZeneca PLC
• Aura Biosciences, Inc.
• Bayer AG
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bristol-Myers Squibb Company
• CNS Pharmaceuticals, Inc.
• Curtana Pharmaceuticals
• Dr. Reddy's Laboratories Ltd.
• Eisai Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GE HealthCare Technologies Inc.
• Gentech, Inc.
• GlaxoSmithKline PLC
• Illumina, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co. Inc.
• Merck KGaA
• Novartis AG
• Novocure GmbH
• Pfizer Inc.
• Qiagen N.V.
• Sanofi S.A.
• Siemens Healthcare GmbH
• Y-mAbs Therapeutics, Inc.

LIST OF FIGURES

• FIGURE 1. BRAIN TUMOR THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. BRAIN TUMOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. BRAIN TUMOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BRAIN TUMOR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BRAIN TUMOR THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 47. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 48. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 74. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 75. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 79. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 80. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 164. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 165. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 166. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 167. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 185. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 186. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 190. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 191. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 192. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 238. BRAIN TUMOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 239. BRAIN TUMOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Brain Tumor Therapeutics Market was valued at USD 3.03 billion in 2023, expected to reach USD 3.28 billion in 2024, and is projected to grow at a CAGR of 8.24%, to USD 5.28 billion by 2030.

The scope and definition of the brain tumor therapeutics market encompass a range of treatments including pharmaceuticals, surgical interventions, and radiation therapies aimed at managing and potentially curing brain tumors. The necessity for these treatments arises from the increasing prevalence of brain tumors worldwide, underscored by the complex nature of these conditions, requiring specialized treatments. The application and end-use scope of brain tumor therapeutics are primarily in hospitals, specialized cancer treatment centers, and research institutions, where the focus is on both immediate patient care and long-term research into more effective treatments. Key influencing growth factors in the market include technological advancements in drug development, such as targeted therapies and immunotherapies, increased investment in research and development by pharmaceutical companies, and rising awareness about early diagnosis and treatment options. Potential opportunities lie in the growing adoption of personalized medicine approaches and the integration of artificial intelligence for better diagnostic and treatment accuracy. However, challenges such as high treatment costs, regulatory hurdles, and the complexity of clinical trials impose significant limitations on market growth. Furthermore, the heterogeneity of brain tumors and the blood-brain barrier pose specific scientific challenges to developing efficacious treatments. To overcome these, the best areas of innovation and research include exploring novel treatment methods like gene therapy, nanoparticle-based drug delivery systems, and the use of biomarkers for precision medicine. These innovations could not only enhance treatment efficacy but also reduce side effects associated with traditional therapies. The nature of the market is highly competitive, driven by continuous advancements and acquisitions aimed at expanding product portfolios. To harness growth, stakeholders should focus on strategic partnerships for R&D, seek to streamline clinical trials, and invest in scalable, cost-effective therapies that address the unmet needs in treating various types of brain tumors.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain Tumor Therapeutics Market

The Brain Tumor Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of brain cancer and other neurological disorders
  • Rising need for tests detecting the presence of tumors
  • Research activities in the molecular diagnostics
• Market Restraints
  • High cost associated with the diagnosis and treatment
• Market Opportunities
  • Rising healthcare expenditure and the favorable reimbursement policies
  • Government initiatives for cancer awareness
• Market Challenges
  • Side effects associated with brain tumor therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Brain Tumor Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain Tumor Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain Tumor Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain Tumor Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain Tumor Therapeutics Market

A detailed market share analysis in the Brain Tumor Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain Tumor Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain Tumor Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain Tumor Therapeutics Market

A strategic analysis of the Brain Tumor Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain Tumor Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adcendo ApS, AIVITA Biomedical, Inc., Amgen Inc., AstraZeneca PLC, Aura Biosciences, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, CNS Pharmaceuticals, Inc., Curtana Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Eisai Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc., Gentech, Inc., GlaxoSmithKline PLC, Illumina, Inc., Johnson & Johnson Services, Inc., Merck & Co. Inc., Merck KGaA, Novartis AG, Novocure GmbH, Pfizer Inc., Qiagen N.V., Sanofi S.A., Siemens Healthcare GmbH, and Y-mAbs Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Brain Tumor Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Glioblastoma, Meningioma, Metastatic Brain Tumors, and Pituitary Tumors.
• Based on Therapy, market is studied across Chemotherapy, Gene Therapy, Immunotherapy, Radiation Therapy, Targeted Therapy, and Tissue Engineering.
• Based on Patient Age Group, market is studied across Adult and Pediatric.
• Based on Distribution Channel, market is studied across Offline Pharmacies and Online Pharmacies.
• Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of brain cancer and other neurological disorders
    • 5.1.1.2. Rising need for tests detecting the presence of tumors
    • 5.1.1.3. Research activities in the molecular diagnostics
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with the diagnosis and treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising healthcare expenditure and the favorable reimbursement policies
    • 5.1.3.2. Government initiatives for cancer awareness
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated with brain tumor therapeutics
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Brain Tumor Therapeutics Market, by Type

• 6.1. Introduction
• 6.2. Glioblastoma
• 6.3. Meningioma
• 6.4. Metastatic Brain Tumors
• 6.5. Pituitary Tumors

7. Brain Tumor Therapeutics Market, by Therapy

• 7.1. Introduction
• 7.2. Chemotherapy
• 7.3. Gene Therapy
• 7.4. Immunotherapy
• 7.5. Radiation Therapy
• 7.6. Targeted Therapy
• 7.7. Tissue Engineering

8. Brain Tumor Therapeutics Market, by Patient Age Group

• 8.1. Introduction
• 8.2. Adult
• 8.3. Pediatric

9. Brain Tumor Therapeutics Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Offline Pharmacies
• 9.3. Online Pharmacies

10. Brain Tumor Therapeutics Market, by End-User

• 10.1. Introduction
• 10.2. Ambulatory Surgical Centers
• 10.3. Hospitals
• 10.4. Specialty Clinics

11. Americas Brain Tumor Therapeutics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Brain Tumor Therapeutics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Brain Tumor Therapeutics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Adcendo ApS
• 3. AIVITA Biomedical, Inc.
• 4. Amgen Inc.
• 5. AstraZeneca PLC
• 6. Aura Biosciences, Inc.
• 7. Bayer AG
• 8. Becton, Dickinson and Company
• 9. Bio-Rad Laboratories, Inc.
• 10. Bristol-Myers Squibb Company
• 11. CNS Pharmaceuticals, Inc.
• 12. Curtana Pharmaceuticals
• 13. Dr. Reddy's Laboratories Ltd.
• 14. Eisai Inc.
• 15. Eli Lilly and Company
• 16. F. Hoffmann-La Roche AG
• 17. GE HealthCare Technologies Inc.
• 18. Gentech, Inc.
• 19. GlaxoSmithKline PLC
• 20. Illumina, Inc.
• 21. Johnson & Johnson Services, Inc.
• 22. Merck & Co. Inc.
• 23. Merck KGaA
• 24. Novartis AG
• 25. Novocure GmbH
• 26. Pfizer Inc.
• 27. Qiagen N.V.
• 28. Sanofi S.A.
• 29. Siemens Healthcare GmbH
• 30. Y-mAbs Therapeutics, Inc.